Prognostic Value of MicroRNAs in Coronary Artery Diseases: A Meta-Analysis

Ji Suk Kim1,2, Kyoungjune Pak1,3, Tae Sik Goh1,4

  • 1BEER, Busan Society of Evidence-based Mdicine and Research, Busan, Korea.

Abstract

Insights

This study confirms microRNA 133a has prognostic value in coronary artery disease (CAD) patients, associating its high expression with increased mortality. It corrects errors in a previous meta-analysis, providing accurate miRNA prognostic data for CAD.

Area of Science:

  • Biomedical research
  • Cardiovascular medicine
  • Molecular biology

Background:

  • Coronary artery diseases (CADs) are a leading global cause of mortality.
  • MicroRNAs (miRNAs) are increasingly recognized as potential biomarkers for cardiovascular prognosis.
  • Previous meta-analyses on miRNA prognostic value in CAD have contained significant errors.

Purpose of the Study:

  • To conduct an updated systematic review and meta-analysis of the prognostic value of altered miRNAs in patients with CAD.
  • To correct inaccuracies identified in a prior meta-analysis concerning miRNA and CAD prognosis.
  • To provide reliable data on the association between specific miRNAs and clinical outcomes in CAD.

Main Methods:

  • Systematic literature search of MEDLINE and EMBASE databases up to May 2017.
  • Inclusion of studies reporting survival data or major adverse cardiac events (MACEs) in CAD patients with miRNA analysis.
  • Independent data extraction by two reviewers and pooled hazard ratio (HR) calculation using a fixed-effect model.

Main Results:

  • Eight studies were included after reviewing 515 articles.
  • High expression of miRNA 133a was significantly associated with increased mortality (pooled HR, 2.35; 95% CI, 1.56-3.55).
  • Elevated levels of several other miRNAs (e.g., 208b, 126, 197) were linked to higher mortality, while others (e.g., 208b, 499-5p, 134) were associated with MACEs.

Conclusions:

  • MicroRNA 133a demonstrates significant prognostic value in coronary artery disease patients, particularly regarding mortality.
  • This updated meta-analysis provides corrected and accurate information on miRNA prognostic implications in CAD.
  • The findings underscore the potential of specific miRNAs as biomarkers for risk stratification in CAD.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.2K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
516
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
298
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
411
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
733
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.3K